Düsseldorf (Germany), March 17, 2016 – GEA has received a EUR 4.5 million
pharmaceutical solid dosage technology order from Zhejiang Hisun Pharmaceutical Co. Ltd (Hisun) in China for high-containment granulation, coating and drying solutions, taking the company’s total investment in GEA to more than EUR 50 million since 2009.
Expanding its current production capacity for oncology treatments, Hisun has placed a new order for four complete high-containment solid dosage granulation, coating and drying lines. Incorporating GEA’s proprietary PharmaConnect™ and FlexStream™ equipment, and machinery manufactured in Europe, this order is the latest addition to a significant number of purchases for multiple pharmaceutical technologies made by Hisun during a longstanding and successful partnership with GEA.
Hisun was established in 1956 and currently employs more than 5,000 people. The company has evolved into one of the largest bulk active pharmaceutical ingredient (API) manufacturers in China, with approximately 80% of its API output being exported to North and South America, Europe and Asia.
Solid and liquid dosage forms
Jinbin Tang, Vice President, Application Center (APC) Pharma China at GEA, commented: “Hisun is GEA’s most important pharmaceutical customer in China. We’ve been working together since 2009 in a variety of different application areas, including solid and liquid dosage forms, and biopharmaceuticals, with a strong focus on freeze drying. Offering finished dosage forms such as capsules, tablets and parenterals, Hisun’s products include antibiotics, anti-infectives, cardiovascular and oncology treatments, making them an ideal partner for GEA’s extensive portfolio of pharmaceutical manufacturing solutions.”
Throughout the well-established and successful relationship with GEA, Hisun has invested in a wide range of the company’s equipment, including 10 state-of-the-art lyophilization production lines with the latest high-specification loading systems and isolators, and high-containment granulation lines.
Operational reliability and trust
Frans K.A. Maas, Vice President, APC Pharma Solids at GEA, added: “During the course of our relationship, which is based on proven performance, operational reliability and trust in GEA’s capability to deliver, Hisun has become a hugely important client. We are honored to be included in Hisun’s selection process and be their pharmaceutical technology supplier of choice for secondary processing lines. Having purchased machinery that has been engineered and assembled in both Europe and China, such as tablet presses and lyophilization lines, with a combined value of more than EUR 50 million since 2009, we’re delighted to continue and expand on this ongoing collaboration.”
Leading in providing process technology
This project illustrates GEA’s leading capability in providing process technology and solutions for the pharmaceutical, biopharmaceutical, biotechnology and nutraceutical industries. The portfolio includes single units, modular systems and complete production lines for powder processing, oral solid dosage forms, parenterals, sterile liquids and semi-solids.